Clinical Trial Central Laboratory Services Market To Reach $6.97 Billion By 2030

Clinical Trial Central Laboratory Services Market Growth & Trends

The global clinical trial central laboratory services market size is expected to reach USD 6.97 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing number of clinical trials, rising demand for biomarker-based testing, stringent regulatory requirements, and growing adoption of decentralized trials. Moreover, technological advancements such as AI-driven analytics, automation, and digital lab management systems further enhance efficiency, reduce turnaround times, and improve overall trial outcomes.

The market is expanding rapidly due to the increasing number of drug development programs and growing investments in research and development. Pharmaceutical and biotechnology companies are conducting more clinical trials to bring innovative therapies to market, further driving the demand for specialized laboratory services. Biomarker-based testing, genomic analysis, and pharmacokinetics studies are becoming essential for clinical trials, requiring advanced lab capabilities. Regulatory authorities are imposing stringent guidelines for drug approval, making centralized laboratory services critical for ensuring compliance, data accuracy, and standardized testing procedures.

Furthermore, the shift toward decentralized and virtual trials further transforms the industry, increasing the need for efficient sample collection, real-time data integration, and remote testing solutions. Emerging technologies such as AI-driven analytics, automation, and digital lab management systems enhance operational efficiency and accelerate trial timelines. Moreover, strategic collaborations between pharmaceutical companies, CROs, and central lab providers strengthen laboratory networks and expand global testing capabilities. The growing focus on personalized medicine and precision therapies continues to fuel demand for high-quality laboratory services, accelerating the industry’s significant growth.

Key market players are adopting various strategies to strengthen their market position. These include strategic partnerships, mergers and acquisitions, and expanding laboratory networks to enhance global reach. Companies also invest in advanced technologies such as AI-driven analytics, automation, and biomarker-based testing to improve efficiency and accuracy. For instance, in February 2025, LabConnect entered into a partnership agreement with Sapio Sciences to implement a Laboratory Information Management System (LIMS). This collaboration aims to further digitally transform complex research workflows, streamlining sample tracking and enhancing data management within LabConnect's operations.

 Request a free sample copy or view report summary: Clinical Trial Central Laboratory Services Market Report

Clinical Trial Central Laboratory Services Market Report Highlights

• Based on service, biomarker testing services dominated the market due to genomic and molecular testing advancements. Regulatory agencies are also encouraging biomarker-based drug approvals, further fueling the market expansion

• Based on the phase, Phase III held the largest market share in 2024 due to the high volume of samples and extensive testing requirements. The growing number of late-stage trials and regulatory mandates further drive demand for central lab services

• Based on Indication, frozen held the largest market share in 2024 due to the rising prevalence of cancer and increasing clinical trials for novel therapies. The growing focus on personalized medicine and biomarker-based diagnostics has amplified the demand for specialized laboratory testing

• Based on end use, pharmaceutical & biopharmaceutical companies held the largest market share in 2024 due to their high R&D investments and extensive clinical trial pipelines. The increasing demand for specialized testing, biomarker analysis, and precision medicine further strengthened their reliance on central labs

Clinical Trial Central Laboratory Services Market Segmentation

Grand View Research has segmented the global clinical trial central laboratory services market based on service, phase, indication, end-use, and region:

Clinical Trial Central Laboratory Services Service Outlook (Revenue, USD Million, 2018 - 2030)

• Biomarker Testing Services

• Microbiology Services

• Anatomic Pathology/Histology

• Pharmacokinetics/Pharmacodynamics (PK/PD)

• Genomic and Molecular Testing

• Sample Collection and Processing

• Logistics & Sample Management

• Data Management & Reporting

• Others

Clinical Trial Central Laboratory Services Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

Clinical Trial Central Laboratory Services Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cardiology

• Neurology

• Infectious Diseases

• Immunology & Autoimmune Diseases

• Others

Clinical Trial Central Laboratory Services End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical and Biotechnology Companies

• Contract Research Organizations

• Others

Clinical Trial Central Laboratory Services By Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Mexico

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• Australia

• South Korea

• Thailand

• Latin America

• Brazil

• Argentina

• Middle East and Africa (MEA)

• South Africa

• Saudi Arabia

• UAE

• Kuwait 

List of Key Players in the Clinical Trial Central Laboratory Services Market

• Labcorp

• ICON plc

• Eurofins Scientific

• Thermo Fisher Scientific Inc.

• Medpace

• Q² Solutions

• Syneos Health

• Charles River Laboratories

• SGS

• LabConnect